Skip to main content
. 2010 Mar 15;107(12):5652–5657. doi: 10.1073/pnas.0910720107

Fig. 7.

Fig. 7.

In vivo demonstration of mechanism of action. The beneficial effect of BMSCs on inflammatory changes is eliminated in the presence of TGF-β neutralizing antibodies, but spared when animals are treated with anti-IL-10 antibodies (A and B). BMSCs from TGF-β or STAT6 deficient animals did not induce TGF-β production (C) or decrease BAL total cell numbers (D), eosinophil numbers (E), cytokine levels (F and G), or serum immunoglobulin concentrations (HJ).